menu
    • menu
    [{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Premier Research Group | Egetis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tiratricol","moa":"NR1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egetis Therapeutics \/ Premier Research Group | Egetis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Premier Research Group | Egetis Therapeutics"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"AnovoRx | Egetis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tiratricol","moa":"NR1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egetis Therapeutics \/ AnovoRx | Egetis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ AnovoRx | Egetis Therapeutics"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Tiratricol","moa":"Thyroid hormone receptor beta","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","highestDevelopmentStatusID":"8","companyTruncated":"Egetis Therapeutics \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Tiratricol","moa":"Thyroid hormone receptor beta","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw","highestDevelopmentStatusID":"8","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw"}]

    Find Clinical Drug Pipeline Developments & Deals for Tiratricol

    Menu

    Tiratricol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : AnovoRx | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

                            Details : Tiratricol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Allan-Herndon-Dudley syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2023

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : AnovoRx | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Premier Research Group | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

                            Details : Tiratricol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Allan-Herndon-Dudley syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 13, 2022

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Premier Research Group | Egetis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Triac Trial II in MCT8 Deficiency Patients

                            Details : Triac is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Allan-Herndon-Dudley syndrome.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 24, 2015

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Country arrow
                            CPhI India
                            Not Confirmed

                            Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients

                            Details : Triac is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Allan-Herndon-Dudley syndrome.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            February 12, 2014

                            Lead Product(s) : Tiratricol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth